Comparison of two analytical platforms for CSF biomarkers of Alzheimer's disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Monge Argilés, Jose Antonio ^a   Muñoz Ruiz, Carlos ^a   Sánchez Payá, José ^a   Gasparini Berenguer, Ruth ^a   Blanco Cantó, Maria Empar ^a   Leiva Santana, Carlos ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PHOSPHORYLATED TAU 181 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXECUTIVE FUNCTION; FEMALE; GERIATRIC DEPRESSION SCALE; HUMAN; LEARNING; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CEREBROSPINAL FLUID LEVEL; PSYCHOLOGIC TEST; SPINAL ANESTHESIA; AREA UNDER THE CURVE; CHEMICAL ANALYSIS; COMPARATIVE STUDY; DEMOGRAPHY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC;

AGED; ALZHEIMER DISEASE; AREA UNDER CURVE; BIOLOGICAL MARKERS; CHEMISTRY TECHNIQUES, ANALYTICAL; DEMOGRAPHY; FEMALE; HUMANS; MALE; ROC CURVE;

EID: 84902275846     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/765130     Document Type: Article

References (10)

1. Blennow K., Hampel H., CSF markers for incipient Alzheimer's disease. The Lancet Neurology 2003 2 10 605 613 2-s2.0-0141738373 10.1016/S1474-4422(03) 00530-1
2. Weiner H. L., Frenkel D., Immunology and immunotherapy of Alzheimer's disease. Nature Reviews Immunology 2006 6 404 416 10.1038/nri1843
3. 42 and tau proteins. Clinical Chemistry 2007 53 5 859 865 2-s2.0-34248327182 10.1373/clinchem.2006.081679
4. McKhann G. M., Knopman D. S., Chertkow H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011 7 3 263 269 10.1016/j.jalz.2011.03.005
5. Albert M. S., DeKosky S. T., Dickson D., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011 7 3 270 279 10.1016/j.jalz.2011.03.008
6. 181 for identifying Alzheimer disease amyloid plaque pathology. Archives of Neurology 2011 68 9 1137 1144 2-s2.0-80052775337 10.1001/archneurol.2011.105
7. Morales-Gonzalez J. M., Gonzalez-Montalvo J. I., del Ser Quijano T., Bermejo-Pareja F., Estudio de validación del S-IQCODE: la versión Española del iformant questionnaire on cognitive decline in the elderly. Archivos de Neurobiología 1992 55 262 266
8. 181) in cerebrospinal fluid by the xMAP technology. Clinical Chemistry 2005 51 2 336 345 2-s2.0-12944312683 10.1373/clinchem.2004.039347
9. Wang L. S., Leung Y. Y., Chang S. K., Comparison of xMAP and ELISA assays for detecting CSF biomarkers of Alzheimer's disease. Journal of Alzheimer's Disease 2012 31 439 445
10. 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Archives of Neurology 2012 69 8 1018 1025 2-s2.0-84863617038 10.1001/archneurol.2012.26